Compare UCL & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UCL | ADVB |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | Hong Kong | Hong Kong |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 8.6M |
| IPO Year | 2019 | 2023 |
| Metric | UCL | ADVB |
|---|---|---|
| Price | $0.24 | $3.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 372.5K | 15.3K |
| Earning Date | 11-11-2026 | 10-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3431.25 |
| EPS | N/A | ★ 5.33 |
| Revenue | N/A | ★ $127,637.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.99 | N/A |
| P/E Ratio | $13.72 | ★ $0.92 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $3.66 |
| 52 Week High | $2.63 | $113.80 |
| Indicator | UCL | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 25.84 | 23.26 |
| Support Level | N/A | $3.86 |
| Resistance Level | $0.44 | $5.59 |
| Average True Range (ATR) | 0.02 | 0.48 |
| MACD | 0.00 | -0.15 |
| Stochastic Oscillator | 10.37 | 8.94 |
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data-related products globally. Its uCloudlink cloud SIM platform is designed for shared mobile data connectivity services by allocating the SIM cards remotely and dynamically to users. Ucloudlink's core business is to provide mobile data connectivity services at competitive prices, which it delivers through a range of hardware products and service solutions to its business partners, retail, and enterprise customers. The main hardware terminals offered by the company include portable Wi-Fi terminals, smartphones, and smart-hardware products for international and local mobile data connectivity services. Geographically, it generates maximum revenue from Japan.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.